naluzotan
Small moleculeexperimental
Naluzotan is a serotonergic drug of the phenylpiperazine class that was under investigation by EPIX Pharmaceuticals Inc for the treatment of generalized anxiety disorder and major depressive disorder. It acts as a selective and potent 5-HT1A receptor partial agonist, readily stimulating prolactin responses, though it has also been found to bind to and activate the σ receptor. — Wikipedia
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2005 (NCT00248183)
Timeline
Indications
Mechanism of action
HTR1A agonist
Development stopped, not superior enough to placebo.
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)Nc1cccc(N2CCN(CCCCNS(=O)(=O)CC3CCCCC3)CC2)c1- Mol. weight
- 450.65 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNaluzotan ↗
- ChEMBLCHEMBL209821 ↗
Also known as
- n-(3-(4-(4-cyclohexylmethanesulfonylaminobutyl)piperazin-1-yl)phenyl)acetamide
- naluzotan
- naluzotan
- naluzotan
- prx00023
- prx 00023
- prx-00023
- prx-00023
- prx-00023
- prx-00023
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01281956 | Phase 2 | Jan 7, 2011 | National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT00448292 | Phase 2 | Mar 1, 2007 | Epix Pharmaceuticals |
| NCT00248183 | Phase 3 | Aug 1, 2005 | Epix Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Epix Pharmaceuticals | For profit | 2 | 2 | 2 | 2005 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 2011 |
2 organizations
Page 1 / 1